mogamulizumab + docetaxel

Mogamulizumab + docetaxel is a **combination therapy** consisting of **mogamulizumab**, a humanized defucosylated monoclonal antibody against C-C chemokine receptor type 4 (CCR4), and **docetaxel**, a microtubule inhibitor classified as a taxane chemotherapy. Mogamulizumab acts primarily via antibody-dependent cellular cytotoxicity by targeting CCR4-expressing cells, such as malignant T cells and regulatory T cells, leading to their depletion. Docetaxel disrupts microtubule function, inhibiting cell division and inducing cancer cell death. The combination is considered for use in cancers such as cutaneous T-cell lymphomas (CTCL, including Sézary syndrome) and potentially other solid tumors, especially in relapsed or refractory disease settings. Clinical evidence for this specific combination is currently limited; most available data report the use of mogamulizumab in combination with other systemic therapies, and there is no established superior efficacy or widespread clinical approval for the mogamulizumab + docetaxel combination at this time[2][3].